Cosmo Pharmaceuticals N.V.
CMOPF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 1.20 | -3.30 | -0.15 |
| FCF Yield | 14.83% | 2.39% | 2.45% | 0.38% |
| EV / EBITDA | 6.13 | 36.48 | 22.35 | 58.64 |
| Quality | ||||
| ROIC | 21.57% | -3.59% | 2.72% | 1.28% |
| Gross Margin | 92.55% | 57.60% | 81.62% | 76.73% |
| Cash Conversion Ratio | 1.06 | 14.82 | 1.36 | 0.53 |
| Growth | ||||
| Revenue 3-Year CAGR | 37.74% | 12.55% | 18.76% | 1.36% |
| Free Cash Flow Growth | 756.04% | -29.34% | 531.02% | -16.18% |
| Safety | ||||
| Net Debt / EBITDA | -0.25 | -2.46 | -0.26 | -1.61 |
| Interest Coverage | 1,182.85 | 0.72 | 3.06 | 1.23 |
| Efficiency | ||||
| Inventory Turnover | 1.47 | 2.77 | 1.63 | 1.15 |
| Cash Conversion Cycle | 106.94 | 162.18 | 214.12 | 354.53 |